Connect with us

Hi, what are you looking for?


Whats Trending

Intranasal Vaccine —  ‘Game changer’ weapon against Corona?

In January, the Union Health Ministry said that a nasal vaccine candidate has been identified and it could be a “game-changer”.

“A nasal vaccine has been identified. It has come for consideration for phase 1 and phase 2 trials. If it works then it could be a game-changer,” Dr. VK Paul, NITI Aayog member said.

Your mind would be flooded with a lot of questions. In such uncertain times, news of hope towards normalcy is all that we desperately await. Here we tried accumulating answers for all the questions that are important to understand the relevance of the forthcoming intranasal vaccine. A vaccine that is considered to be a — ‘game-changer.’

Why nasal vaccine for Covid-19 likely to be a game-changer? Plus how it will be administered.

As the name suggests, a nasal vaccine is given by the nose, instead of a needle through your arm. It directly delivers the dose to the respiratory pathway, much like a nasal spray. 

The added advantage of a nasal vaccine is that it will be non-invasive and needle-free, unlike the currently administered vaccine through needles. This would also eliminate the possibility of injuries and infections associated with needles. As the nasal vaccine targets to directly go inside the nasal cavity like drops, it wouldn’t require trained healthcare workers for its administration. 

Apart from that, another reason why it is considered a ‘game changer’ is that the nasal vaccine will not only build immunity but will also give protection from coronavirus; unlike the regular vaccines.

What are its doses?

 The intranasal vaccine requires only a single dose of 0.1 ml, using a spray in each of the nostrils. It’s easy administration will allow a large number of people to be immunised. Furthermore, there will be no need to carry two rounds of vaccine administrations.

How does Intra Nasal Vaccine work?

The intranasal vaccine is a live attenuated vaccine, which means it uses a weakened form of the germ, as per a study from the University of Washington’s School of Medicine. It gets absorbed in the mucus membrane, present in the upper throat when it is given through the nose. After its administration, it will be able to develop antibodies, since it enters the mucus membrane directly, the absorption is much faster. It helps develop an immune response in the nose, which is the point of the virus entrance, the study explains.

What is the status of the Nasal vaccine in India?

 In India, Bharat Biotech has applied for phase 1 trials.

As per the company’s official statement, the vaccine has demonstrated promising efficacy in mice and hamster so far; and these species showed immunity with a single dose. Furthermore, it has shown superior protection than the one or two doses of intramuscular vaccines.

According to a media report, Bharat Biotech International Limited said that it wants to develop a vaccine that will be easy to administer like ‘polio drops’.

 Bharat Biotech has begun with the screening process of potential clinical trial participants at four centres in India — Nagpur, Hyderabad, Patna and Chennai for their new nasal vaccine against Covid19.

The number of subjects in the first phase of the nasal vaccine trial would be 125. The product on trial is BBV154, a novel adenovirus vectored, intranasal vaccine, according to reports. 

As per Bharat Biotech’s website, “An intranasal vaccine stimulates a broad immune response neutralising IgG, mucosal IgA, and T cell responses and creates an immune response at the site of infection (in the nasal mucosa) essential for blocking both infection and transmission of Covid-19.”

What is the status globally?

Globally, there are about four intranasal vaccines undergoing phase 1 and phase 2 trials at the moment.

What makes a Nasal vaccine a better option?

The Intranasal vaccine will be a cost-effective option with the added advantage of the ease of administration with no injections.

Apart from that, it kills the virus at the entrance. “The nasal route has excellent potential for vaccination due to the organised immune systems of the nasal mucosa,” says Dr Bagai.

“Eight-two per cent of SARSCoV2 transmission occurs through the nasal passage. It takes 6–15 hours for the virus to zone into hAlveolar type 2 cells in the lungs to precipitate the cytogenetic release to cause ARDS. The concentration of ACE2R is maxed in the nasal passage. The sentinel cells around the nerves are rich in receptors to cause invasion of the host,” explains Dr Bagai, according to a media report. 

“The protein enzyme called Neuropilin is responsible for causing the fusion to the host. Neuropilin is in high concentration in sentinel nasal cells. The IgA maximises in the nasal area by 29 per cent. This causes quicker protection and response to the vaccine. Therefore, it’s a very good move,” says Dr Bagai, the report adds.

The ease of administration without needles, given intranasally will contribute to the vaccine coverage and speed up the process of vaccination drive. The company is working towards a single dose of the nasal vaccine which, if approved, the logistics expenses and cost will also be gashed.

Furthermore, Bharat Biotech says: “The nasal vaccine can have high compliance as it would be ideally suited for children and adults,” 

Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Subscribe to our Newsletter

You May Also Like


Naomi Campbell, Holy Trinity, Claudia are models that come to our mind whenever the topic of 90’s supermodel comes. Of course, they are the...

Whats Trending

It is rightly said, not all superheroes wear a cape, and the superhero I am talking about is an inspiration to many in numerous...

Whats Trending

Evoking the memories of the movement of the 1970s where women formed unprecedented resistance against tyranny by “hugging trees to protect them from being...


For the longest time in history, women are bounded with prejudice, and unfortunately, they still are. But there are women like Dr Richa who...

Font Resize